Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Medicine and Dentistry

• Atypical Hemolytic Uremic Syndrome 100%
• Patient 100%
• Follow up 80%
• Evaluation Study 80%
• Thrombotic Thrombocytopenic Purpura 80%
• Therapeutic Procedure 60%
• Adult 60%
• Analysis 40%
• Hemoglobin 20%
• Serum 20%
• Adverse Event 20%
• Systemic Disease 20%
• Chronic Kidney Disease 20%
• Glomerular Filtration Rate 20%
• Lactate Dehydrogenase 20%
• Platelet 20%
• Kidney Function 20%
• Acute Kidney Injury 20%
• Complement Component C5 20%
• Meningococcal Disease 20%
• Inpatient 20%
• Quality of Life 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Hemolytic Uremic Syndrome 100%
• Thrombotic Thrombocytopenic Purpura 80%
• Ravulizumab 80%
• Clinical Trial 40%
• Lactate Dehydrogenase 20%
• Adverse Event 20%
• Hemoglobin 20%
• Systemic Disease 20%
• Chronic Kidney Failure 20%
• Acute Kidney Failure 20%
• Complement Component C5 20%
• Meningococcosis 20%
• Complement Component C5 Inhibitor 20%